Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Aldose reductase inhibition alone or combined with an adenosine A(3) agonist reduces ischemic myocardial injury.

Autor: Tracey WR; Department of Cardiovascular and Metabolic Diseases, Pfizer, Incorporated, Groton, Connecticut 06340, USA. w_ross_tracey@groton.pfizer.com, Magee WP, Ellery CA, MacAndrew JT, Smith AH, Knight DR, Oates PJ

Publikováno v: American journal of physiology. Heart and circulatory physiology [Am J Physiol Heart Circ Physiol] 2000 Oct; Vol. 279 (4), pp. H1447-52.

Vasoconstrictor action of angiotensin I-convertase and the synthetic substrate (Pro11,D-Ala12)-angiotensin I.

Autor: Mangiapane ML; Department of Cardiovascular and Metabolic Diseases, Pfizer Inc, Groton, CT 06340., Rauch AL, MacAndrew JT, Ellery SS, Hoover KW, Knight DR, Johnson HA, Magee WP, Cushing DJ, Buchholz RA

Publikováno v: Hypertension (Dallas, Tex. : 1979) [Hypertension] 1994 Jun; Vol. 23 (6 Pt 2), pp. 857-60.

Positive correlation between blood pressure or heart rate and chymase-dependent angiotensin II-forming activity in circulating mononuclear leukocytes measured by new ELISA.

Autor: Okamura, Keisuke¹ (AUTHOR) okamurakmd@cis.fukuoka-u.ac.jp, Okuda, Tetsu¹ (AUTHOR), Shirai, Kazuyuki¹ (AUTHOR), Urata, Hidenori¹ (AUTHOR)

Publikováno v: Clinical & Experimental Hypertension. 2018, Vol. 40 Issue 2, p112-117. 6p.

Aldose reductase modulates acute activation of mesenchymal markers via the β-catenin pathway during cardiac ischemia-reperfusion.

Autor: Thiagarajan, Devi¹, O’ Shea, Karen¹, Sreejit, Gopalkrishna¹, Ananthakrishnan, Radha¹ ramasr02@nyumc.org, Quadri, Nosirudeen¹, Li, Qing¹, Schmidt, Ann Marie¹, Gabbay, Kenneth², Ramasamy, Ravichandran¹

Publikováno v: PLoS ONE. 11/30/2017, Vol. 12 Issue 11, p1-17. 17p.